Jiaxian He

Jiaxian He

Auto-generated profile, based on publicly available information

Jiaxian He

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2022 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
RWRobert A. Wise
Robert A. Wise
JHJanet T. Holbrook
Janet T. Holbrook
RBRobert H. Brown
Robert H. Brown
GCGerard J. Criner
Gerard J. Criner
MDMark T. Dransfield
Mark T. Dransfield
LQLoretta G. Que
Loretta G. Que
Rationale: There are no pharmacologic agents that modify emphysema progression in patients with chronic obstructive pulmonary disease (COPD). Objectives: To evaluate the efficacy of losartan, an angiotensin receptor blocker, to reduce emphysema progression. Methods: The trial was a multicenter, randomized, placebo-controlled trial conducted between May 2017 and January 2021. Eligible participants were aged ⩾40 years, had moderate to severe airflow obstruction, ⩾10 pack-years of smoking, mild-moderate emphysema on high-resolution computed tomography, and no medical indication for or intolerance of angiotensin receptor blockers. Treatment with losartan 100 mg daily or matching placebo (1:1) was randomly assigned. The primary outcome was emphysema progression on high-resolution computed tomography over 48 weeks. Secondary outcomes included the St George’s Respiratory Questionnaire, the modified Medical Research Council dyspnea scale, the COPD Assessment Test, and the Physical Function–Short Form 20a. Measurements and Main Results: A total of 220 participants were enrolled; 58% were men, 19% were African American, and 24% were current smokers. The medians (interquartile ranges) for age were 65 (61–73) years and 48 (36–59) for percent predicted FEV1 after bronchodilator use. The mean (95% confidence interval) percentage emphysema progression was 1.35% (0.67–2.03) in the losartan group versus 0.66% (0.09–1.23) in the placebo group (P = NS). Conclusions: Losartan did not prevent emphysema progression in people with COPD with mild-moderate emphysema. Clinical trial registered with www.clinicaltrials.gov (NCT02696564).

1 August 2023 in Respiratory Medicine
Verified
Journal Article
Closed access
DKDavid A. Kaminsky
David A. Kaminsky
JHJiaxian He
Jiaxian He
RHRobert Henderson
Robert Henderson
ADAnne E. Dixon
Anne E. Dixon
CICharles G. Irvin
Charles G. Irvin
JHJanet T. Holbrook
Janet T. Holbrook

22 September 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
IHIssam S. Hamadeh
Issam S. Hamadeh
JPJai Patel
Jai Patel
RJRyan Jacobs
Ryan Jacobs
HZHang Zeng
Hang Zeng
JHJiaxian He
Jiaxian He
NGNilanjan Ghosh
Nilanjan Ghosh
Purpose: Patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib are at risk of developing cardiovascular side effects (CVSE). The molecular determinants of CVSEs have not been fully elucidated. We interrogated genetic polymorphisms in the Bruton tyrosine kinase (BTK) signaling pathway for their association with ibrutinib-related CVSEs. Experimental Design: We conducted a retrospective/prospective observational pharmacogenetic study of 50 patients with newly diagnosed or relapsed CLL who received ibrutinib at a starting daily dose of 420 mg for at least 6 months. CVSEs, primarily atrial fibrillation and hypertension, occurred in 10 patients (20%), of whom 4 discontinued therapy. DNA was isolated from buccal swabs of all 50 patients and genotyped for 40 SNPs in GATA4, SGK1, KCNQ1, KCNA4, NPPA, and SCN5A using a customized next-generation sequencing panel. Univariate and multivariate logistic regression analysis were performed to determine genetic and clinical factors associated with the incidence of ibrutinib-related CVSEs. Results: GATA4 rs804280 AA (P = 0.043), KCNQ1 rs163182 GG (P = 0.036), and KCNQ1 rs2237895 AA (P = 0.023) genotypes were univariately associated with ibrutinib-related CVSEs. On the basis of multivariate analysis, a high genetic risk score, defined as the presence of at least two of these genotypes, was associated with 11.5-fold increased odds of CVSEs (P = 0.019; 95% confidence interval, 1.79–119.73). Conclusions: Our findings suggest possible genetic determinants of ibrutinib-related CVSEs in CLL. If replicated in a larger study, pretreatment pharmacogenetic testing for GATA4 and KCNQ1 polymorphisms may be a useful clinical tool for personalizing treatment selection for CLL and/or instituting early risk mitigation strategies.

22 June 2023 in JMIR Pediatrics and Parenting
Verified
Journal Article
Open access
KBKathryn V Blake
Kathryn V Blake
HAHolly Antal
Holly Antal
HBH Timothy Bunnell
H Timothy Bunnell
JHJiaxian He
Jiaxian He
RHRobert Henderson
Robert Henderson
TWTim Wysocki
Tim Wysocki
Background: Research participants often misunderstand the required elements of informed consent information, whether provided in written or oral format. Informed consent instruments with embedded evidence-based learning theory principles administered in multimedia electronic formats may improve comprehension and retention. Objective: This study aims to determine whether study information comprehension and retention using an interactive multimedia video consent process was noninferior to comprehension and retention after an in-person face-to-face interaction with a conventional written consent document for caregivers and adolescents enrolled in a clinical trial. Methods: Participants were caregivers and children aged 12 to 17 years who were enrolled in a clinical trial of asthma treatment. Consent information was presented as a multimedia web-based video consent interaction or as a conventional written consent document with in-person interaction between the prospective participants and the study staff. The trial used a parallel nonrandomized noninferiority design that compared the 2 consent methods. Caregivers and adolescents completed a 17-item open-ended comprehension questionnaire (score range 17-51) at enrollment and at the end of the study 20 weeks later. Comprehension and retention were compared between the consent formats. Noninferiority was established if the 95% CI upper bound of the difference in scores (conventional format minus web-based) was less than the noninferiority margin of 2.4; superiority was established if the upper bound of the CI was <0. Results: In total, 54 caregiver and adolescent dyads completed the interactive multimedia web-based video consent, and 25 dyads completed the conventional consent. Overall, 33% (26/79) of all adolescents were Black, 57% (45/79) were male, and 61% (48/79) had a household income of <US $60,000 per year. For caregivers, the interactive multimedia web-based format was noninferior to the conventional format at enrollment (difference between the conventional and web-based formats: mean −0.30, 95% CI −2.52 to 1.92) and was superior at the end of the study 20 weeks later (mean −2.20, 95% CI −3.9 to −0.5). There was a loss of comprehension over 20 weeks (mean −1.65, 95% CI −3.1 to −0.19) with the conventional format but not with the multimedia web-based format (mean 0.14, 95% CI −0.84 to 1.12). For adolescents, the noninferiority of the multimedia web-based format was not established. Conclusions: Caregivers who are considering enrolling their adolescent in an asthma clinical trial have similar comprehension of study information when delivered through an interactive multimedia web-based platform, which incorporates evidence-based learning theory principles, compared with having a conventional in-person, face-to-face discussion. The retention of study information over time was better with the multimedia format for caregivers. Trial Registration: ClinicalTrials.gov NCT02061280; https://clinicaltrials.gov/ct2/show/NCT02061280 and NCT01437995; https://clinicaltrials.gov/ct2/show/NCT01437995

25 September 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
MGMichael R. Grunwald
Michael R. Grunwald
WSWei Sha
Wei Sha
JHJiaxian He
Jiaxian He
SSSrinivasa Sanikommu
Srinivasa Sanikommu
JGJonathan M. Gerber
Jonathan M. Gerber
NGNilanjan Ghosh
Nilanjan Ghosh
Using haploidentical donors for allogeneic hematopoietic cell transplantation (HCT) broadens transplant accessibility to a growing number of patients with hematologic disorders. Moreover, haploidentical HCT with post-transplant cyclophosphamide (PTCy) has become widespread practice due to accumulating evidence demonstrating favorable rates of survival and graft-versus-host disease (GvHD). Most studies comparing outcomes by donor sources have been confounded by variability in conditioning regimens, graft type (peripheral blood or bone marrow), and post-transplant GvHD prophylaxis (PTCy or non-PTCy), making it difficult to define the effect of donor source on outcomes. Levine Cancer Institute started a transplant and cellular therapy program in 2014, with both haploidentical and matched related donor (MRD) transplants initially performed using a uniform reduced intensity conditioning (RIC) regimen, peripheral blood grafts, and PTCy-based GvHD prophylaxis. This retrospective observational study was conducted to compare the clinical outcomes associated with RIC haploidentical HCT and MRD HCT in patients receiving identical conditioning regimens, graft types, and supportive care. Our transplant database was queried to evaluate demographic characteristics, clinical features, and outcomes of RIC HCT for consecutive patients with hematologic malignancies who received haploidentical or MRD grafts between March 2014 and December 2017. A MRD was the preferred donor source; when unavailable, a haploidentical donor was used. Sixty-seven patients underwent haploidentical HCT and 25 MRD HCT. Overall, characteristics of transplant recipients were similar for the haploidentical and MRD groups; however, haploidentical donors were younger than MRDs (median 36 years vs 57 years, P <.0001). Results of univariable analysis showed similar overall survival (OS) for haploidentical and MRD HCT (HR, 1.15; 95% CI, 0.61-2.15; P =.669). One-year, three-year, and five-year OS were 80.2%, 54.7%, and 41.2% for haploidentical HCT and 76.0%, 55.7%, and 51.1% for MRD HCT, respectively. With a median follow-up of 81.90 months, results of multivariable analysis revealed that donor source (haploidentical vs MRD) was not significantly associated with OS (HR, 0.97; 95% CI, 0.51-1.87; P =.933), relapse-free survival (HR, 0.75; 95% CI, 0.42-1.35; P =.337), cumulative incidence of relapse (HR, 0.81; 95% CI, 0.39-1.70; P =.579), or non-relapse mortality (HR, 1.12; 95% CI, 0.40-3.14; P =.827). Cumulative incidences of acute GvHD (aGvHD) and chronic GvHD (cGvHD) were not significantly different for haploidentical and MRD HCT (grades II-IV aGvHD: HR, 1.78; 95% CI, 0.72-4.37; P =.210; grades III-IV aGvHD: HR, 2.84; 95% CI, 0.34-23.63; P =.335; cGvHD: HR, 1.00; 95% CI 0.36-2.76; P =.995). With care that was homogenous in terms of conditioning regimens, graft type, GvHD prophylaxis, and supportive care, 92 patients who were biologically randomized to either haploidentical HCT or MRD HCT after RIC with PTCy had comparable outcomes.

1 December 2023
Verified
Other
Open access
IHIssam S. Hamadeh
Issam S. Hamadeh
JPJai Patel
Jai Patel
RJRyan Jacobs
Ryan Jacobs
HZHang Zeng
Hang Zeng
JHJiaxian He
Jiaxian He
NGNilanjan Ghosh
Nilanjan Ghosh
Purpose:Patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib are at risk of developing cardiovascular side effects (CVSE). The molecular determinants of CVSEs have not been fully elucidated. We interrogated genetic polymorphisms in the Bruton tyrosine kinase (BTK) signaling pathway for their association with ibrutinib-related CVSEs.Experimental Design:We conducted a retrospective/prospective observational pharmacogenetic study of 50 patients with newly diagnosed or relapsed CLL who received ibrutinib at a starting daily dose of 420 mg for at least 6 months. CVSEs, primarily atrial fibrillation and hypertension, occurred in 10 patients (20%), of whom 4 discontinued therapy. DNA was isolated from buccal swabs of all 50 patients and genotyped for 40 SNPs in GATA4, SGK1, KCNQ1, KCNA4, NPPA, and SCN5A using a customized next-generation sequencing panel. Univariate and multivariate logistic regression analysis were performed to determine genetic and clinical factors associated with the incidence of ibrutinib-related CVSEs.Results:GATA4 rs804280 AA (P = 0.043), KCNQ1 rs163182 GG (P = 0.036), and KCNQ1 rs2237895 AA (P = 0.023) genotypes were univariately associated with ibrutinib-related CVSEs. On the basis of multivariate analysis, a high genetic risk score, defined as the presence of at least two of these genotypes, was associated with 11.5-fold increased odds of CVSEs (P = 0.019; 95% confidence interval, 1.79–119.73).Conclusions:Our findings suggest possible genetic determinants of ibrutinib-related CVSEs in CLL. If replicated in a larger study, pretreatment pharmacogenetic testing for GATA4 and KCNQ1 polymorphisms may be a useful clinical tool for personalizing treatment selection for CLL and/or instituting early risk mitigation strategies.